Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bexagliflozin 對第二型糖尿病腎臟結局的影響：隨機對照試驗的系統性回顧與統合分析
Cureus 2025-05-19
Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management.
鈉-葡萄糖共轉運蛋白2抑制劑（SGLT2 inhibitors）在代謝性疾病中的雙重益處：糖尿病控制與痛風管理
World J Clin Cases 2025-05-19
**重點整理：**
Lin 等人證實，dapagliflozin（SGLT2 抑制劑）能有效降低尿酸、改善心臟功能，並減少慢性心臟衰竭合併高尿酸血症患者的心血管事件。這項研究也探討了 SGLT2 抑制劑在治療痛風和高尿酸血症的潛力，為臨床實務帶來新的見解。
相關文章PubMedDOI推理
The impact of clinical history on the predictive performance of machine learning and deep learning models for renal complications of diabetes.
臨床病史對機器學習與深度學習模型預測糖尿病腎臟併發症表現的影響
Comput Methods Programs Biomed 2025-05-18
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies.
心臟澱粉樣變性患者使用SGLT2抑制劑的耐受性與療效：觀察性研究的統合分析
Eur Heart J Cardiovasc Pharmacother 2025-05-17